InvestSMART

Truscreen Group Limited (ASX:TRU)

ALERT: Price-sensitive ASX Announcement for TRU
Current share price for TRU : $0.013 -0.003 (-18.75%)+
Announcement
Release
28 Nov 2025 7:30AM
Price at Release
$0.016
Full Release
download
Summary
Truscreen Group Limited, a company specializing in cervical cancer screening technology, reported its unaudited interim financial results for the six months ending on 30 September 2025. The company's revenue was impacted by deferred programs, resulting in a sales revenue decrease of 17% to NZ$860,000, and an operating loss increased to NZ$1.36 million. Despite challenges, Truscreen made significant strategic moves, including a successful capital raise of NZ$4 million and expansion into markets like India and South Africa. It continued to strengthen its presence in China and initiated public screening programs in Vietnam and Zimbabwe. The appointment of new distributors and strategic alliances, such as with Hangzhou Dalton Biosciences Ltd, are expected to enhance market access and HPV product range.
Key Points
  • Truscreen reported a sales revenue of NZ$860,000 for the first half of FY2026.
  • Operating loss increased to NZ$1.36 million due to deferred programs and capital raise costs.
  • Truscreen raised NZ$4 million to support achieving monthly cash flow positive.
  • Strategic expansions in India and South Africa with new distributors appointed.
  • Continued strong performance in China, bolstered by a strategic alliance with DaltonBio.
  • Public screening programs launched in Vietnam and Zimbabwe.
  • Net operating cash outflow was NZ$1.7 million, affected by lower customer receipts and manufacturing prepayments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.